openPR Logo
Press release

Lawsuit filed for Investors in shares of NextCure, Inc. (NASDAQ: NXTC)

09-30-2020 10:02 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in NextCure, Inc. (NASDAQ: NXTC) shares over alleged securities laws violations.

A lawsuit was filed on behalf of investors in NextCure, Inc. (NASDAQ: NXTC) shares over alleged securities laws violations.

An investor, who purchased shares of NextCure, Inc. (NASDAQ: NXTC), filed a lawsuit over alleged violations of Federal Securities Laws by NextCure, Inc., certain directors and officers of the Company, and the underwriters of NextCure’s November 2019 public offering.

Investors who purchased shares of NextCure, Inc. (NASDAQ: NXTC) have certain options and for certain investors are short and strict deadlines running. Deadline: November 20, 2020. NASDAQ: NXTC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Beltsville, MD based NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.

On January 13, 2020, NextCure, Inc. (NASDAQ: NXTC) disclosed in a U.S. Securities and Exchange Commission filing that Eli Lilly and Company had ended its 2018 research and development collaboration agreement with NextCure, Inc.

Then, on July 13, 2020, NextCure, Inc. announced that the Company no longer planned to “advance the non-small cell lung cancer (NSCLC) and ovarian cancer cohorts in the stage 2 portion of the Simon 2-stage trial” for its NC318 immunomedicine product, citing “clinical response data” and “current enrollment criteria.” NextCure concurrently announced the resignation of Kevin N. Heller from his role as the Company’s Chief Medical Officer.

Shares of NextCure, Inc. (NASDAQ: NXTC) declined to as low as $7.91 per share on September 24, 2020.

The plaintiff claims that the defendants violated provisions of the Exchange and Securities Acts by misleading investors regarding its leading treatment candidate, NC318. Specifically, the complaint alleges that statements made by Defendants concerning the effectiveness of NC318, the responses observed in patients treated with NC318, and NC318’s potential to treat patients’ refractory to PD-1 therapies were false and misleading.

Those who purchased shares of NextCure, Inc. (NASDAQ: NXTC) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of NextCure, Inc. (NASDAQ: NXTC) here

News-ID: 2147612 • Views:

More Releases from Shareholders Foundation

Investigation announced for Investors in shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) over possible Violations of Securities Laws
Investigation announced for Investors in shares of Lifecore Biomedical, Inc. (NA …
An investigation was announced for investors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) shares over potential securities laws violations by Lifecore Biomedical, Inc. Investors who purchased shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Lifecore Biomedical, Inc. regarding its business, its prospects and
Investigation announced for Investors in shares of Designer Brands Inc. (NYSE: DBI) over potential Wrongdoing by certain directors
Investigation announced for Investors in shares of Designer Brands Inc. (NYSE: D …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Designer Brands Inc. Investors who purchased shares of Designer Brands Inc. (NYSE: DBI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Designer Brands Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders. Columbus,
Lawsuit Alert: Investors who lost money with shares of Innoviz Technologies Ltd. (NASDAQ: INVZ) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Innoviz Technologies Ltd. …
An investor, who purchased shares of Innoviz Technologies Ltd. (NASDAQ: INVZ), filed a lawsuit over alleged violations of Federal Securities Laws by Innoviz Technologies Ltd. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Innoviz Technologies Ltd. (NASDAQ: INVZ) have certain options and for certain investors are short and strict deadlines running. Deadline: May 14, 2024. NASDAQ: INVZ investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Lawsuit filed for Investors who lost money with shares of iRobot Corporation (NASDAQ: IRBT)
Lawsuit filed for Investors who lost money with shares of iRobot Corporation (NA …
An investor, who purchased shares of iRobot Corporation (NASDAQ: IRBT), filed a lawsuit over alleged violations of Federal Securities Laws by iRobot Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of iRobot Corporation (NASDAQ: IRBT) have certain options and for certain investors are short and strict deadlines running. Deadline: May 7, 2024. NASDAQ: IRBT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)

All 5 Releases


More Releases for NextCure

Tumor Immunotherapy Market 2022: Covid-19 Impact, Competitive Landscape, Growth …
Global Tumor Immunotherapy Market Research Report provides a key analysis of the market status of the Tumor Immunotherapy with the best facts and figures, meaning, definition, SWOT analysis, expert opinions, and the latest developments across the globe. The report also calculates the market size, Sales, Price, Revenue, Gross Margin, Market Share, cost structure, and growth rate. The report considers the revenue generated from the sales of this Report and technologies
Investigation announced for Long-Term Investors in NextCure, Inc. (NASDAQ: NXTC)
An investigation on behalf of current long-term investors in shares of NextCure, Inc. (NASDAQ: NXTC) concerning potential breaches of fiduciary duties by certain directors and officers of NextCure, Inc. (NASDAQ: NXTC was announced. Investors who are current long term investors in NextCure, Inc. (NASDAQ: NXTC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current
Investigation announced for Long-Term Investors in shares of NextCure, Inc. (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of NextCure, Inc.. Investors who are current long term investors in NextCure, Inc. (NASDAQ: NXTC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: NXTC stocks follows a lawsuit filed against NextCure, Inc. over alleged securities
Deadline on Nov. 20th coming up in Lawsuit filed for Investors in NextCure, Inc. …
A deadline is coming up on November 20, 2020 in the lawsuit filed for certain investors of NextCure, Inc. (NASDAQ: NXTC). Investors who purchased shares of NextCure, Inc. (NASDAQ: NXTC) have certain options and there are strict and short deadlines running. Deadline: November 20, 2020. NASDAQ: NXTC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the complaint filed in the U.S. District Court for
Clinical Trials Market Study Offers In-depth Competitive Landscape Assessment 20 …
Collaboration at Its Peak: Key Strategy of Manufacturers in Clinical Trials Market For reducing economic burden, many companies are planning to shift their focus towards on-core business activities, thereby outsourcing their clinical trials activities to the CROs (contract research organizations). This in turn influences biotechnology and pharmaceutical companies for outsourcing clinical trials activities to the CROs in APAC. Major CROs are approached by the drug companies at a notable rate for
Clinical Trials Market: 2018-2028: Dynamics, Forecast, Analysis and Supply Deman …
Collaboration at Its Peak: Key Strategy of Manufacturers in Clinical Trials Market For reducing economic burden, many companies are planning to shift their focus towards on-core business activities, thereby outsourcing their clinical trials activities to the CROs (contract research organizations). This in turn influences biotechnology and pharmaceutical companies for outsourcing clinical trials activities to the CROs in APAC. Major CROs are approached by the drug companies at a notable rate for